Q-omics provides the consensus-scored PIK3C2A profile across patient tissues and cancer cell-line models. PIK3C2A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PIK3C2A is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, PIK3C2A RNA expression shows 21,539 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where PIK3C2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIK3C2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIK3C2A survival associations across molecular data types. PIK3C2A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (12) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIK3C2A RNA expression–survival associations across cancer types. High PIK3C2A expression shows unfavorable associations in UVM, MESO and LIHC, but favorable associations in KIRC, READ and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PIK3C2A RNA expression.
This table summarizes PIK3C2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PIK3C2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIK3C2A shows lower tumor expression in THCA, LUAD, KIRC and KIRP and higher tumor expression in LIHC and CHOL. The THCA box plot shows higher PIK3C2A RNA expression in normal versus tumor tissue (log2 FC = −1.192, t-test p < 0.001).
This table shows molecular features associated with PIK3C2A in patient tissues and cancer cell lines. In patient samples, PIK3C2A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PIK3C2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
